
|Videos|December 13, 2022
CheckMate 9ER: Long-Term Follow-Up Data
Author(s)Eric Jonasch, MD
Dr Eric Jonasch reviews key efficacy and safety outcomes of the long term follow-up data from CheckMate 9ER and discusses the rationale for evaluating cabozantinib plus nivolumab in patients with advanced RCC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































